Comparative Pharmacology
Head-to-head clinical analysis: MARINOL versus PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MARINOL versus PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE.
MARINOL vs PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dronabinol is a cannabinoid receptor agonist at CB1 and CB2 receptors. It stimulates appetite and reduces nausea/vomiting via central CB1 receptor activation.
Phenylephrine is a selective alpha-1 adrenergic receptor agonist causing vasoconstriction; promethazine is a phenothiazine derivative that blocks histamine H1 receptors and has anticholinergic, antiemetic, and sedative effects.
Dronabinol (Marinol) 2.5 mg orally twice daily, titrated to 5–20 mg daily in divided doses; max 20 mg/day. For chemotherapy-induced nausea/vomiting: 5 mg/m² orally 1–3 hours before chemotherapy, then every 2–4 hours up to 6 doses/day. For anorexia: 2.5 mg orally twice daily (before lunch and dinner).
IV: 0.1-0.5 mg phenylephrine and 12.5-25 mg promethazine as a single dose.
None Documented
None Documented
Dronabinol terminal half-life is 25–36 hours in adults, with a prolonged elimination phase (25–36 h) due to enteric recirculation. Chronic users may exhibit a shorter half-life due to enzyme induction.
Phenylephrine: 2-3 hours (terminal). Promethazine: 10-14 hours (terminal in adults; prolonged in elderly and hepatic impairment).
Primarily fecal (65%) with biliary excretion; renal excretion of metabolites accounts for ~20% (mostly as glucuronide conjugates). Less than 5% of unchanged drug is excreted renally.
Phenylephrine: renal (80% as unchanged drug and sulfate conjugates). Promethazine: renal (70-80% as metabolites and unchanged drug), fecal (20-30%).
Category C
Category A/B
Antiemetic
Antihistamine / Antiemetic